Identification of novel antitubercular compounds through hybrid virtual screening approach.

[1]  James I. Fells,et al.  Structure-based drug design identifies novel LPA3 antagonists. , 2009, Bioorganic & medicinal chemistry.

[2]  Joel S. Freundlich,et al.  Triclosan Derivatives: Towards Potent Inhibitors of Drug‐Sensitive and Drug‐Resistant Mycobacterium tuberculosis , 2009, ChemMedChem.

[3]  Marcel L. Verdonk,et al.  Protein-Ligand Docking against Non-Native Protein Conformers , 2008, J. Chem. Inf. Model..

[4]  P. Tonge,et al.  Inhibitors of FabI, an enzyme drug target in the bacterial fatty acid biosynthesis pathway. , 2008, Accounts of chemical research.

[5]  P. Ortiz de Montellano,et al.  Inhibition of the Mycobacterium tuberculosis enoyl acyl carrier protein reductase InhA by arylamides. , 2007, Bioorganic & medicinal chemistry.

[6]  James C. Sacchettini,et al.  Mechanism of thioamide drug action against tuberculosis and leprosy , 2007, The Journal of experimental medicine.

[7]  Robert Stroud,et al.  Pyrrolidine carboxamides as a novel class of inhibitors of enoyl acyl carrier protein reductase from Mycobacterium tuberculosis. , 2006, Journal of medicinal chemistry.

[8]  K. Mdluli,et al.  Novel targets for tuberculosis drug discovery. , 2006, Current opinion in pharmacology.

[9]  David Rogers,et al.  Cheminformatics analysis and learning in a data pipelining environment , 2006, Molecular Diversity.

[10]  S. Gillespie,et al.  Tuberculosis drug development pipeline: progress and hope , 2006, The Lancet.

[11]  Feng Wang,et al.  Hydrogen peroxide-mediated isoniazid activation catalyzed by Mycobacterium tuberculosis catalase-peroxidase (KatG) and its S315T mutant. , 2006, Biochemistry.

[12]  Thierry Kogej,et al.  Multifingerprint Based Similarity Searches for Targeted Class Compound Selection , 2006, J. Chem. Inf. Model..

[13]  S. Kaufmann,et al.  CORRIGENDUM: Annulling a dangerous liaison: vaccination strategies against AIDS and tuberculosis , 2005, Nature Medicine.

[14]  J. Skolnick,et al.  TM-align: a protein structure alignment algorithm based on the TM-score , 2005, Nucleic acids research.

[15]  Claudio N. Cavasotto,et al.  Protein flexibility in ligand docking and virtual screening to protein kinases. , 2004, Journal of molecular biology.

[16]  S. Kageyama,et al.  Characterization of clinical isolates of Mycobacterium tuberculosis resistant to drugs and detection of RpoB mutation in multidrug-resistant tuberculosis in the Philippines. , 2003, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[17]  S. Parikh,et al.  Inhibition of InhA, the enoyl reductase from Mycobacterium tuberculosis, by triclosan and isoniazid. , 2000, Biochemistry.

[18]  C. Vilchèze,et al.  Crystal Structure of the Mycobacterium tuberculosis Enoyl-ACP Reductase, InhA, in Complex with NAD+ and a C16 Fatty Acyl Substrate* , 1999, The Journal of Biological Chemistry.

[19]  L. Collins,et al.  Microplate alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium , 1997, Antimicrobial agents and chemotherapy.

[20]  W. Jacobs,et al.  inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. , 1994, Science.

[21]  Alan Forrest,et al.  Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.